Search results
Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients - British...
Nature· 2 days agoTregs trafficking is controlled by CXCR4. In Renal Cell Carcinoma (RCC), the effect of the new CXCR4 antagonist, R54, was explored in ...
Moderna plants new solid tumor trials for cancer vaccine, weeds PD-1 work after review
FierceBiotech· 3 days agoModerna detailed plans for its individual neoantigen cancer vaccine in a first-quarter earnings...
Afinitor interactions: Other medications, alcohol, and more
Medical News Today· 2 days agoAfinitor has interactions with some other drugs and certain supplements. Before you start treatment...
CD70 Antibodies CD70 Targeting Therapies Clinical Trials Market Opportunity Insight
Benzinga· 4 days agoDelhi, May 01, 2024 (GLOBE NEWSWIRE) -- Global CD70 Targeting Therapies Market Opportunity & Clinical Trials Insight 2024 Report Highlights: CD70 Targeting Therapies In Clinical Trials: > 20 TherapiesCD 70
Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 5 days agoMerck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript April 25, 2024 Merck & Co., Inc. beats...
Sutent Dosage: Form, Strengths, How to Take, and More
Healthline· 4 days agoSutent is a prescription drug used to treat certain types of cancer. Learn about the drug's dosages, form, strengths, how to take it, and more.
Exelixis (NASDAQ:EXEL) Earns “Outperform” Rating from William Blair
ETF DAILY NEWS· 2 days agoWilliam Blair reaffirmed their outperform rating on shares of Exelixis (NASDAQ:EXEL – Free Report) in a report published on Wednesday, RTT News reports. Barclays lowered Exelixis from an overweight ...
Short Interest in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Rises By 5.6%
ETF DAILY NEWS· 4 days agoIovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) saw a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 48,980,000 shares ...
New York State Common Retirement Fund Sells 5,141 Shares of Iovance Biotherapeutics, Inc....
ETF DAILY NEWS· 3 days agoNew York State Common Retirement Fund trimmed its holdings in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 0.5% during the 4th quarter, according to the company in ...